IFRX vs IGC

InflaRx N.V. vs IGC Pharma, Inc. — Valuation Comparison 2026

IFRX

Biotechnology
InflaRx N.V.
Quality
1.8
out of 10
Value Trap
Price
$2.38
Last close
Models
7/13
Active
VS

IGC

Biotechnology
IGC Pharma, Inc.
Quality
5.4
out of 10
Value Trap
38
LOW
Price
$0.29
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType IFRX Fair ValueIFRX Upside IGC Fair ValueIGC Upside
Bayesian DCF Intrinsic $0.63 -73.5% $0.08 -73.3%
Earnings Power Value Intrinsic $0.09 -72.7%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $0.89 -65.3% $0.30 +3.7%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IFRX vs IGC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IFRX vs IGC — Which Stock Is More Undervalued?

IGC scores higher with a 5.4/10 quality rating vs IFRX's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing InflaRx N.V. (IFRX) and IGC Pharma, Inc. (IGC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IFRX currently trades at $2.38 with a QOC of 1.8/10, while IGC trades at $0.29 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).